首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1410100

青光眼治療市場：2023年至2028年預測

Glaucoma Treatment Market - Forecasts from 2023 to 2028

出版日期: 2023年12月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2021年青光眼治療市場規模達20.47億美元。

預計青光眼治療市場在預測期內將顯著成長。青光眼一詞是指一組損害眼睛視神經的疾病。青光眼是最常見的視神經損傷類型，會導致視力喪失。主要治療目標是降低眼壓。這是透過減少房水的分泌或增加其排水來實現的。急性鬱血性青光眼、慢性青光眼、隅角閉鎖性青光眼和開放性青光眼是青光眼的其他類別。

青光眼治療市場的主要成長動力

青光眼盛行率的增加、醫療費用的上升、診斷技術的改進、有利的報銷實踐等都促進了青光眼治療市場的成長。此外，新藥物配方的可得性和青光眼治療技術的開拓，例如微創青光眼手術（MIGS）設備和緩釋性藥物輸送系統，正在推動青光眼治療市場的擴張。

青光眼患者增加

青光眼盛行率的增加預計將影響青光眼治療市場。根據美國國家醫學圖書館的數據，60 歲以上的人、已被診斷患有青光眼的人的家庭成員、類固醇使用者、患有糖尿病、高度近視、高血壓和中央角膜的人是青光眼的高危險群。厚度5毫米。低於100%，如傷眼。預計2020年將有7,600萬人患有青光眼，到2040年將增加到1.118億。

預計老年人口的增加將提振市場。

人口老化將顯著推動青光眼治療市場的發展。老齡化相關的因素增加了青光眼的盛行率，導致新藥的需求增加以及與眼部保健相關的醫療費用增加。此外，根據 2017 年聯合國報告，預計該疾病的盛行率在未來幾年將會上升，60 歲及以上人口將從 2017 年的 12.7% 增加到 2050 年的 21.3%。老年人常遇到各種健康問題，包括青光眼與其他老齡化相關疾病並存，因此需要徹底、全面的治療方法。

Gland素類似物預計將大幅成長

Gland素類似物對於控制眼壓和延遲發病至關重要，對青光眼治療市場有重大影響。青光眼治療行業由於其廣泛使用和患者依從性的提高而整體成長，因為與某些替代方案相比，其優越的療效和較低的副作用。Gland類似物的廣泛使用正在影響市場動態和治療模式，並刺激青光眼治療的研究和開發。

預計技術進步將刺激青光眼治療市場

市場形勢的技術進步徹底改變了形勢，為診斷、監測和治療性介入提供了創新的解決方案。對創新手術方法的需求預計將推動青光眼治療市場的成長。醫學影像、光同調斷層掃瞄（OCT）、微創青光眼手術（MIGS）、選擇性雷射海綿體成形術（SLT）和進展分析軟體的進步將進一步增加對驗光師的需求。

對高效青光眼處方眼藥水的需求不斷成長

青光眼治療市場的市場參與企業和主要參與企業正在努力開發創新藥物組合和處方眼藥水，以儘早控制青光眼。一些生物醫學和製藥公司正在致力於產品開發，以減輕醫療機構的負擔。這些用於治療青光眼的藥物包括BETA阻斷劑、碳酸酐酶抑制劑、α促效劑、膽鹼能促效劑、Gland類似物 (PGA) 和某些聯合治療。這些藥物透過促進液體從患者眼睛中排放幫助降低眼內壓。

管道療法代表著巨大的市場機會

針對當前疾病的各種管道治療是預測期內青光眼治療市場成長的主要驅動力。其中之一是由明尼蘇達大學藥學院治療發現與開發研究所 (ITDD) 和藥物化學系開發的一種用於治療青光眼的全新藥物。正在開發的主要青光眼治療藥物有拉坦前列素、鹽酸利帕舒地爾水合物、PH-011、PH-012、甲磺酸奈達舒地爾、拉坦前列素、（Bimatoprost+噻嗎洛爾）和（拉坦前列素+奈達舒地爾）。

預計北美市場將顯著成長

北美青光眼治療市場成長的關鍵因素之一是先進的醫院診斷基礎設施和高效的治療系統。此外，該地區不斷增加的 FDA核准和藥物上市也支持了成長。

市場主要發展

2023 年 4 月，三一學院的遺傳學家開發了一種治療青光眼的新基因療法。 2022年7月，艾伯維與iSTAR Medical達成策略協議，將MINIject®設備商業化，這是一種針對青光眼患者的微創青光眼手術器械。 2022年4月，Skye Bioscience選擇CMAX臨床研究進行SBI-100眼用乳劑的1期研究。 Skye 得到了 CMAX 的支持，CMAX 是世界上最著名的專門從事早期試驗的臨床實驗營運商之一。

The glaucoma treatment market is anticipated to grow significantly during the forecast period. The term glaucoma refers to a collection of conditions that harm the optic nerve in the eyes. It is the most typical type of optic nerve injury that results in visual loss. Lowering intraocular tension is the major treatment objective. This is accomplished by either decreasing aqueous humour secretion or enhancing drainage. Acute congestive glaucoma, chronic glaucoma, angle-closure glaucoma, and open-angle glaucoma are other categories of glaucoma.

Major growth drivers for the glaucoma treatment market

The increased prevalence of glaucoma, rising healthcare costs, improvements in diagnostic techniques, and favourable reimbursement practices are all contributing to the growth of the glaucoma treatment market. In addition, the availability of novel medication formulations and technical developments in glaucoma therapies, such as minimally invasive glaucoma surgery (MIGS) devices and sustained-release drug delivery systems, are propelling the glaucoma treatment market's expansion.

Increasing prevalence of people suffering from glaucoma

The growing prevalence of glaucoma among people is anticipated to impact the glaucoma treatment market. According to the National Library of Medicine, a higher risk of glaucoma is associated with elderly over 60, family members of those already diagnosed with the condition, steroid users, diabetics, high myopia, hypertension, central corneal thickness less than 5 mm, and ocular trauma. It is projected that 76 million individuals had glaucoma in 2020, and by 2040, the figure is anticipated to rise to 111.8 million.

Growth in the geriatric population is predicted to fuel the market.

The market for glaucoma treatments is greatly boosted by the aging population as age-related factors increase the prevalence of glaucoma, which in turn drives demand for novel medicines and raises healthcare costs associated with eye care. Furthermore, according to a 2017 United Nations report, the prevalence of the disease is predicted to rise in the coming years as the population aged 60 and above rises from 12.7% in 2017 to 21.3% by 2050. A thorough and integrated approach to therapy is required since the senior population frequently experiences various health issues, including the coexistence of glaucoma with other age-related disorders.

Prostaglandin Analogs is anticipated to grow significantly

Prostaglandin analogues, which are essential for controlling intraocular pressure and delaying the onset of the condition, have had a significant effect on the market for glaucoma treatments. The glaucoma pharmaceutical industry has grown as a whole and patient compliance has risen as a result of its widespread usage due to its excellent effectiveness and low adverse effect profile when compared to certain alternatives. Prostaglandin analogues' widespread use has impacted market dynamics and treatment patterns and has fueled glaucoma therapy research and development.

Advancements in technology are predicted to fuel the glaucoma treatment market

Technological advancements in the glaucoma treatment market have revolutionized the landscape, providing innovative solutions for diagnosis, monitoring, and therapeutic interventions. The demand for innovative surgical methods is anticipated to fuel glaucoma treatment market growth. The advancements in medical imaging, optical coherence tomography (OCT), micro-invasive glaucoma surgery (MIGS), selective laser trabeculoplasty (SLT), and progression analysis software further increase the demand for optometrists.

Growing demand for efficient prescription eye drops for glaucoma

Manufacturers and major market participants in the glaucoma treatment market are working to develop innovative medication combinations and prescription eye drops to control glaucoma at an early stage. To ease the burden on healthcare facilities, several biomedical and pharmaceutical companies engage in product development. Several of these medications used to treat glaucoma include beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cholinergic, prostaglandin analogues (PGAs), and certain combination treatments. These drugs assist in reducing intraocular pressure by encouraging fluid evacuation from the patient's eye.

Pipeline therapy is a major market opportunity

The various pipeline therapies for the currently developing disease are the primary drivers of the glaucoma treatment market growth over the forecast period. One such development is a brand-new medicine for the treatment of glaucoma that was developed by the Institute for Therapeutics Discovery & Development (ITDD) and the Department of Medicinal Chemistry at the University of Minnesota College of Pharmacy. The leading glaucoma drugs in development were latanoprost, ripasudil hydrochloride hydrate, PH-011, PH-012, netarsudil mesylate, latanoprost, (bimatoprost + timolol), and (latanoprost + netarsudil).

North America is anticipated to show significant growth in the market

One of the main factors contributing to North America's glaucoma treatment market growth is its sophisticated hospital diagnosis infrastructure and efficient treatment framework. Furthermore, the growth is being supported by the increasing number of FDA approvals and medicine launches for the treatment in the area.

Market Key Developments

In April 2023, new novel gene therapy for glaucoma was developed by Trinity College geneticists.
In July 2022, AbbVie and iSTAR Medical formed a strategic agreement to commercialise the MINIject® device, a less invasive glaucoma surgical tool for glaucoma patients.
In April 2022, to carry out the Phase 1 study for SBI-100 Ophthalmic Emulsion, Skye Bioscience chose CMAX clinical research. Skye got assistance from CMAX, one of the most renowned trial operators in the world which specialises in early-phase studies.

Segmentation:

By Disease Type

Open Angle Glaucoma
Angle Closure Glaucoma
Others

By Drug Class

Prostaglandins Analogs
Beta-blockers
Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GLAUCOMA TREATMENT MARKET BY DISEASE TYPE

5.1. Introduction
5.2. Open Angle Glaucoma
5.3. Angle Closure Glaucoma
5.4. Others

6. GLAUCOMA TREATMENT MARKET BY DRUG CLASS

6.1. Introduction
6.2. Prostaglandins Analogs
6.3. Beta-blockers
6.4. Adrenergic Agonists
6.5. Carbonic Anhydrase Inhibitors
6.6. Others

7. GLAUCOMA TREATMENT MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy

8. GLAUCOMA TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others